XERS Stock Analysis: Buy, Sell, or Hold?

XERS - Xeris Biopharma Holdings, Inc. Common Stock

PHARMACEUTICAL PREPARATIONS
$7.36
0.12 (1.66%) ▲
BUY
HIGH Confidence
Last Updated: January 30, 2026
Earnings: Mar 02, 2026 29d

Get Alerted When XERS Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.
100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading chart...

Loading historical data...

💡
Bottom Line:
✅ BUY SIGNAL: XERS shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

0% (Stagnation) 50% (Hyper Growth)
EST. PRICE IN 2031
$13.54
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$8.40
12.4% Margin of Safety

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 22.1x Exit PE.

In-depth Analysis How we analyze

Valuation Analysis: XERS is currently trading at $7.36, which is considered slightly low relative to its 30-day fair value range of $7.19 to $7.73. The stock's valuation (Forward PE: 23.0) is in line with its historical norms (22.1). At these levels, the market is pricing in 1.4% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.

Technical Outlook: Technically, XERS is in a downtrend. Immediate support is located at $7.04, while resistance sits at $7.85.

Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $11.14 (+53.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.

Quick Decision Summary

Current Position SLIGHTLY LOW
Fair Price Range $7.19 - $7.73
Company Quality Score 46/100 (HOLD)
Volume Confirmation HIGH
Confidence Score 80.5%

All Signals

  • BULLISH: Price oversold vs 30-day range
  • NEUTRAL: Mixed technical signals (40/100)
  • BULLISH: High volume confirmation
  • BULLISH: Trading 53.9% below Wall St target ($11.14)
  • NEUTRAL: Market pricing in 1.4% annual earnings growth - fairly valued

Fair Price Analysis

30-Day Fair Range $7.19 - $7.73
Current vs Fair Value SLIGHTLY LOW

Support & Resistance Levels

Support Level $7.05
Resistance Level $7.85
Current Trend Downtrend

Fundamental Context

Forward P/E (Next Year Est.) 23.02
Wall Street Target $11.14 (+53.9%)
Revenue Growth (YoY) 37.1%
Profit Margin -5.9%
Valuation Premium vs History +1.4% premium
PE vs Historical 23.0 vs 22.1 FAIR
Market-Implied Price Targets If current PE multiple persists
Implied Growth (YoY): +1.4% (market-implied from PE analysis)
1-Year Target $7.34 (+1%)
2-Year Target $7.44 (+3%)
3-Year Target $7.55 (+4%)
3-Yr Target (if PE normalizes) (PE: 23→22) PE COMPRESSION $7.25 (+0%)
Earnings growth offset by PE compression
3-Year Scenarios Using analyst projected EPS growth
Bull: (PE: 23.0, Growth: 399.2%) $24.44 (+238%)
Base: (SPY PE: 22.3, Growth: 399.2%) $23.67 (+227%)
Bear: (PE: 19.0, Growth: 399.2%) $20.12 (+178%)
Last updated: January 30, 2026 7:34 PM ET
Data refreshes hourly during market hours. Next update: 8:34 PM
🔥 Top Stocks Breaking Out Now
Ticker Score Recommendation Change %
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Marla Persky SELL 15500 shares 2025-09-11
Jeffrey W Sherman SELL 42232 shares 2025-08-28
John Johnson SELL 107500 shares 2025-08-13

Featured in Portfolios

XERS is a key holding in these high-performance investment strategies.

Top Rated Biotechnology Stocks

Top-rated stocks in Biotechnology by analyst ratings.

Stock Analyst Consensus Analyst Target Tradestie Score
NTLA
Intellia Therapeutics Inc
STRONG BUY
29 analysts
$22 60 HOLD
ARGX
argenx NV ADR
STRONG BUY
22 analysts
$1035 58 HOLD
CRSP
Crispr Therapeutics AG
BUY
28 analysts
$83 57 HOLD
DNLI
Denali Therapeutics Inc
STRONG BUY
19 analysts
$33 60 HOLD
KYMR
Kymera Therapeutics Inc
STRONG BUY
20 analysts
$117 59 HOLD

Advanced XERS Option Strategies

Professional options setups generated by AI based on today's XERS price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for XERS

XERS Technical Chart XERS Price Prediction XERS Earnings Date XERS Investment Advisor XERS Fair Price Analyzer XERS Options Advisor XERS Options Chain XERS Options Analysis XERS Competitors
Live Trades
From trading groups
Loading trades...
View All Live Trades See Trader Consensus & Signals